Encycle Therapeutics Overview
- Year Founded
-
2012

- Status
-
Acquired/Merged
- Employees
-
6

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$80M
Encycle Therapeutics General Information
Description
Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane-permeable and orally bioavailable products thereby, enabling patients to get cured of inflammatory bowel disease and other inflammatory disorders.
Contact Information
Website
www.encycletherapeutics.comCorporate Office
- 101 College Street
- Suite 314
- Toronto, Ontario M5G 1L7
- Canada
Corporate Office
- 101 College Street
- Suite 314
- Toronto, Ontario M5G 1L7
- Canada
Encycle Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Merger/Acquisition | 22-Oct-2019 | $80M | Completed | Generating Revenue | ||
5. Corporate | 01-Nov-2017 | Completed | Generating Revenue | |||
4. Early Stage VC | 30-Sep-2015 | Completed | Startup | |||
3. Early Stage VC | 16-Jun-2015 | Completed | Startup | |||
2. Grant | 17-Nov-2014 | $2.5M | Completed | Startup | ||
1. Early Stage VC | 11-Nov-2014 | $2.5M | $2.5M | Completed | Startup |
Encycle Therapeutics Comparisons
Industry
Financing
Details
Encycle Therapeutics Competitors (17)
One of Encycle Therapeutics’s 17 competitors is Apeptico, a Venture Capital-Backed company based in Vienna, Austria.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Apeptico | Venture Capital-Backed | Vienna, Austria | ||||
Cyclenium Pharma | Corporate Backed or Acquired | Montreal, Canada | ||||
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
Oncorus | Formerly VC-backed | Andover, MA |
Encycle Therapeutics Patents
Encycle Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-2967750-A1 | Solid phase synthesis of cyclic amino acid molecules | Inactive | 19-Nov-2014 | ||
EP-3221335-A1 | Solid phase synthesis of cyclic amino acid molecules | Inactive | 19-Nov-2014 | ||
EP-3221335-A4 | Solid phase synthesis of cyclic amino acid molecules | Inactive | 19-Nov-2014 | ||
US-20170320908-A1 | Solid phase synthesis of cyclic amino acid molecules | Inactive | 19-Nov-2014 | C07K1/1077 |
Encycle Therapeutics Signals
Encycle Therapeutics Former Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Accel-Rx | Accelerator/Incubator | Minority | ||
BDC Capital | Growth/Expansion | Minority | ||
CQDM | Other | Minority | ||
MaRS Investment Accelerator Fund | Venture Capital | Minority | ||
Merck & Co. | Corporation |
Encycle Therapeutics FAQs
-
When was Encycle Therapeutics founded?
Encycle Therapeutics was founded in 2012.
-
Where is Encycle Therapeutics headquartered?
Encycle Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Encycle Therapeutics?
Encycle Therapeutics has 6 total employees.
-
What industry is Encycle Therapeutics in?
Encycle Therapeutics’s primary industry is Drug Discovery.
-
Is Encycle Therapeutics a private or public company?
Encycle Therapeutics is a Private company.
-
What is the current valuation of Encycle Therapeutics?
The current valuation of Encycle Therapeutics is
. -
What is Encycle Therapeutics’s current revenue?
The current revenue for Encycle Therapeutics is
. -
How much funding has Encycle Therapeutics raised over time?
Encycle Therapeutics has raised $5.99M.
-
Who are Encycle Therapeutics’s investors?
Accel-Rx, BDC Capital, CQDM, MaRS Investment Accelerator Fund, and Merck & Co. are 5 of 9 investors who have invested in Encycle Therapeutics.
-
Who are Encycle Therapeutics’s competitors?
Apeptico, Cyclenium Pharma, Alnylam Pharmaceuticals, Rein Therapeutics, and Oncorus are some of the 17 competitors of Encycle Therapeutics.
-
When was Encycle Therapeutics acquired?
Encycle Therapeutics was acquired on 22-Oct-2019.
-
Who acquired Encycle Therapeutics?
Encycle Therapeutics was acquired by Zealand Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »